Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to
determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to
evaluate the preliminary efficacy for each combination regimen.